• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

铂化合物在癌症化疗中应用的临床前研究视角

Preclinical perspectives on the use of platinum compounds in cancer chemotherapy.

作者信息

Farrell Nicholas P

机构信息

Department of Chemistry, Virginia Commonwealth University, Richmond, VA 23298, USA.

出版信息

Semin Oncol. 2004 Dec;31(6 Suppl 14):1-9. doi: 10.1053/j.seminoncol.2004.11.004.

DOI:10.1053/j.seminoncol.2004.11.004
PMID:15726528
Abstract

Although platinum compounds have long been used in cancer chemotherapy, understanding the biochemistry and specific activity of these agents remains a focus of ongoing research, particularly with regard to next-generation platinum agents. This review will examine current knowledge and recent studies of the molecular mechanisms of platinum DNA damage and repair, including novel platinum DNA targets. Gene expression associated with platinum DNA damage will also be explored, as well as mechanisms of platinum-drug delivery, drug resistance, and future directions in the development of novel platinum agents.

摘要

尽管铂类化合物长期以来一直用于癌症化疗,但了解这些药物的生物化学和特定活性仍然是正在进行的研究重点,特别是对于下一代铂类药物而言。本综述将审视关于铂类DNA损伤与修复分子机制的现有知识和近期研究,包括新型铂类DNA靶点。还将探讨与铂类DNA损伤相关的基因表达,以及铂类药物递送、耐药性机制,以及新型铂类药物开发的未来方向。

相似文献

1
Preclinical perspectives on the use of platinum compounds in cancer chemotherapy.铂化合物在癌症化疗中应用的临床前研究视角
Semin Oncol. 2004 Dec;31(6 Suppl 14):1-9. doi: 10.1053/j.seminoncol.2004.11.004.
2
Nucleotide excision repair pathway review I: implications in ovarian cancer and platinum sensitivity.核苷酸切除修复途径综述I:对卵巢癌和铂敏感性的影响
Gynecol Oncol. 2007 Oct;107(1 Suppl 1):S56-71. doi: 10.1016/j.ygyno.2007.07.043. Epub 2007 Sep 19.
3
Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: a review.人类肿瘤对铂类抗癌药物的耐药机制:综述
J Otolaryngol. 1995 Aug;24(4):242-52.
4
Platinum-based anticancer agents: innovative design strategies and biological perspectives.铂类抗癌药物:创新设计策略与生物学视角
Med Res Rev. 2003 Sep;23(5):633-55. doi: 10.1002/med.10038.
5
[Platinum salts: cytotoxic mechanisms of action, mechanisms of resistance of cancer cells, interactions with ionizing radiation, specificity of carboplatin].[铂盐:细胞毒性作用机制、癌细胞耐药机制、与电离辐射的相互作用、卡铂的特异性]
Bull Cancer. 2000 Aug;87 Spec No:7-15.
6
The resurgence of platinum-based cancer chemotherapy.基于铂的癌症化疗的复兴。
Nat Rev Cancer. 2007 Aug;7(8):573-84. doi: 10.1038/nrc2167. Epub 2007 Jul 12.
7
Molecular mechanisms of platinum resistance: still searching for the Achilles' heel.铂耐药的分子机制:仍在寻找阿喀琉斯之踵。
Drug Resist Updat. 2004 Aug-Oct;7(4-5):227-32. doi: 10.1016/j.drup.2004.08.002.
8
The development of platinum compounds and their possible combination.铂化合物的发展及其可能的组合。
Crit Rev Oncol Hematol. 2006 Oct;60(1):59-75. doi: 10.1016/j.critrevonc.2006.02.003. Epub 2006 Jun 27.
9
Recent updates in the clinical use of platinum compounds for the treatment of gynecologic cancers.铂类化合物在妇科癌症治疗中临床应用的最新进展。
Semin Oncol. 2004 Dec;31(6 Suppl 14):17-24. doi: 10.1053/j.seminoncol.2004.11.007.
10
Cellular processing of platinum anticancer drugs.铂类抗癌药物的细胞处理过程。
Nat Rev Drug Discov. 2005 Apr;4(4):307-20. doi: 10.1038/nrd1691.

引用本文的文献

1
Will the Interactions of Some Platinum (II)-Based Drugs with B-Vitamins Reduce Their Therapeutic Effect in Cancer Patients? Comparison of Chemotherapeutic Agents such as Cisplatin, Carboplatin and Oxaliplatin-A Review.某些基于铂 (II) 的药物与 B 族维生素的相互作用是否会降低癌症患者的治疗效果?顺铂、卡铂和奥沙利铂等化疗药物的比较——综述。
Int J Mol Sci. 2023 Jan 12;24(2):1548. doi: 10.3390/ijms24021548.
2
Affinities to Oxaliplatin: Vitamins from B Group vs. Nucleobases.奥沙利铂亲和力:B 族维生素与核苷碱基。
Int J Mol Sci. 2022 Sep 12;23(18):10567. doi: 10.3390/ijms231810567.
3
The 5'UTR variant of ERCC5 fails to influence outcomes in ovarian and lung cancer patients undergoing treatment with platinum-based drugs.
ERCC5 的 5'UTR 变异未能影响接受铂类药物治疗的卵巢癌和肺癌患者的结局。
Sci Rep. 2016 Dec 14;6:39217. doi: 10.1038/srep39217.
4
Evaluation of platinum chemotherapy in combination with HER2-targeted α-particle radiation.评价铂类化疗联合 HER2 靶向α粒子放疗。
Cancer Biother Radiopharm. 2013 Jul-Aug;28(6):441-9. doi: 10.1089/cbr.2012.1423. Epub 2013 Jun 11.
5
Oxaliplatin: pre-clinical perspectives on the mechanisms of action, response and resistance.奥沙利铂:作用机制、反应及耐药性的临床前研究视角
Ecancermedicalscience. 2009;3:153. doi: 10.3332/ecancer.2009.153. Epub 2009 Sep 24.
6
Characteristic effect of an anticancer dinuclear platinum(II) complex on the higher-order structure of DNA.抗癌双核铂(II)配合物对 DNA 高级结构的特征性影响。
J Biol Inorg Chem. 2010 Jun;15(5):701-7. doi: 10.1007/s00775-010-0637-y. Epub 2010 Mar 17.
7
In Vitro Evaluation of Oxoplatin: An Oral Platinum(IV) Anticancer Agent.奥沙铂的体外评价:一种口服铂(IV)类抗癌剂。
Met Based Drugs. 2009;2009:348916. doi: 10.1155/2009/348916. Epub 2009 Jun 30.
8
More pronounced salt dependence and higher reactivity for platination of the hairpin r(CGCGUUGUUCGCG) compared with d(CGCGTTGTTCGCG).与d(CGCGTTGTTCGCG)相比,发夹结构r(CGCGUUGUUCGCG)对铂化作用表现出更明显的盐依赖性和更高的反应活性。
J Biol Inorg Chem. 2006 Nov;11(8):974-90. doi: 10.1007/s00775-006-0157-y. Epub 2006 Sep 5.